Abstract
Congenital infection by Toxoplasma gondii is a leading cause of visual impairment in children and the most frequent infectious etiology. Although congenital toxoplasmosis may affect many organs, eye manifestations are the most common. Lesions of retinochoroiditis affect visual function according to their localization relative to the macula and to the optic disc. After the neonatal period, scarred lesions of retinochoroiditis may reactivate or new lesions may appear. Therefore, in cases of congenital toxoplasmosis, even when fundus examination is normal at birth, a careful long-term ophthalmic follow-up is necessary.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Mets MB, Holfels E, Boyer KM, Swisher CN, Roizen N, Stein L, Stein M, Hopkins J, Withers S, Mack D, Luciano R, Patel D, Remington JS, Meier P, McLeod R (1996) Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol 122:309–324
Rothova A, Meenken C, Buitenhuis HJ, Brinkman CJ, Baarsma GS, Boen-Tan TN, de Jong PT, Klaassen-Broekema N, Schweitzer CM, Timmerman Z et al (1993) Therapy for ocular toxo-plasmosis. Am J Ophthalmol 115:517–523
Ronday MJ, Luyendijk L, Baarsma GS, Bollemeijer JG, Van der Lelij A, Rothova A (1995) Presumed acquired ocular toxoplasmosis. Arch Ophthalmol 113:1524–1529
Couvreur J, Thulliez P (1996) Toxoplasmose acquise à localisation oculaire ou neurologique. 49 cas. Presse Med 25:438–442
Glasner PD, Silveira C, Kruszon-Moran D, Martins MC, Burnier Junior M, Silveira S, Camargo ME, Nussenblatt RB, Kaslow RA, Belfort Junior R (1992) An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol 114:136–144
Dutton GN, Hay J, Hair DM, Ralston J (1986) Clinicopathological features of a congenital murine model of ocular toxoplasmosis Graefe’s. Arch Clin Exp Ophthalmol 224:256–264
Gazzinelli RT, Brezin AP, Li Q, Nussenblatt RB, Chan CC (1994) Toxoplasma gondii: acquired ocular toxoplasmosis in the murine model, protective role of TNF-alpha and IFN-gamma. Exp Parasitol 78:217–229
Brézin AP, Kasner L, Thulliez P, Li Q, Daffos F, Nussenblatt RB, Chan CC (1994) Ocular toxoplasmosis in the fetus: Immunohistochemistry analysis and DNA amplification. Retina 14:19–26
Roberts F, McLeod R (1999) Pathogenesis of toxoplasmic retinochoroiditis. Parasitology Today 15:51–57
Courgenay A (1997) Évaluation du coût de la prévention et de la prise en charge de la toxoplamose congénitale en France. Thèse pour le Diplôme dtat de Docteur e’État de Docteur en Médecine. Université Paris Val-de-Marne, Faculté de Médecine Créteil
Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H (1986) Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1(8475):254–256
Koppe JG, Rothova (1989) A Congenital toxoplasmosis. A long-term follow-up of 20 years. Int Ophthalmol 13:387–390
Meenken C, Assies J, van Nieuwenhuizen O, Holwerda-van der Maat WG, van Schooneveld MJ, Delleman WJ, Kinds G, Rothova A (1995) A Long term ocular and neurological involvement in severe congenital toxoplasmosis. Br J Ophthalmol 79:581–584
Couvreur J, Desmonts G, Aron-Rosa D (1985) Le pronostic oculaire de la toxoplasmose congénitale: rôle du traitement. Sem Hôp Paris 61:1734–1737
Hohlfeld P, Daffos F, Thulliez P, Aufrant J, Couvreur J, Mac Meese D, Descombey D, Forestier F (1989) Fetal toxoplasmosis: Outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 115:765–769
Daffos F, Forestier F, Capella-Pavlovsky M, Thulliez P, Aufrant C, Valenti D, Cox WL (1988) Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med 318:271–275
Brézin AP, Thulliez P, Couvreur J, Nobré R, McLeod R, Mets M (1998) Ophthalmic outcome after pre-and post-natal treatment of congenital toxoplasmosis. Invest Ophthalmol Vis Sci 394:2986 [ARVO Abstract]
Kaufman HE (1961) The penetration of daraprim (pyrimethionine) into the monkey eye. Am J Ophthalmol 52:402–404
Brihaye M, De Meuter F, Tassignon MJ, Braeckman C, Mercier A, Van Hoof F (1980) Étude de la pénétration intra-oculaire de médicaments à effet thérapeutique sur la toxoplasmose. Etude préliminaire. Bull Soc Belge Ophtal 191:39–43
Gormley PD, Pavesio CE, Minnasian D, Lightman S (1998) Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Invest Ophthalmol Vis Sci 39:1171–1175
Engstrom RE Jr, Holland GN, Nussenblatt RB, Jabs DA (1991) Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 111:601–610
Pearson PA, Piracha AR, Sen HA, Jaffe GJ (1999) Atovaquone for the treatment of Toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 106:148–153
Araujo FG, Huskinson J, Remington JS (1991) Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566 C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother 35:293–299
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag France
About this paper
Cite this paper
Brézin, A.P. (2000). Ophthalmology in the neonate with congenital toxoplasmosis. In: Ambroise-Thomas, P., Petersen, P.E. (eds) Congenital toxoplasmosis. Springer, Paris. https://doi.org/10.1007/978-2-8178-0847-5_13
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0847-5_13
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-59664-3
Online ISBN: 978-2-8178-0847-5
eBook Packages: Springer Book Archive